Alerta

FORMULATIONS OF AN ANTIVIRAL PRODRUG

Resumen de: AU2024239507A1

Disclosed herein, in part, are pharmaceutical compositions comprising a prodrug of an antiviral agent and methods of using the same in the treatment of viral infections.

BIODEGRADABLE DENDRITIC PARTICLES FOR SUSTAINED DRUG RELEASE

Resumen de: WO2024192288A2

Described herein are methods, systems and compositions for the production and use of a class of highly branched, nanostructured particles, generally referred to herein as dendritic particles (DPs), synthesized from biodegradable materials that are specifically adapted for drug release in vivo.

NANOBODY-BASED PROTEIN DEGRADERS AND RELATED METHODS

Resumen de: WO2024192235A2

The present disclosure relates compositions comprising and/or encoding nanodegraders (ND) and methods of use thereof.

COMPOUND OR SALT THEREOF, LIPID COMPOSITION, PHARMACEUTICAL COMPOSITION, AND DELIVERY CARRIER

Resumen de: EP4682138A1

An object of the present invention is to provide a compound or a salt thereof, which constitutes a lipid composition capable of realizing a high nucleic acid encapsulation rate and excellent nucleic acid delivery in a case where mRNA is used; and a lipid composition, a pharmaceutical composition, and a delivery carrier, which are capable of realizing a high nucleic acid encapsulation rate and excellent nucleic acid delivery in a case where mRNA is used. According to the present invention, a compound represented by Formula (1) or a salt thereof is provided.In the formula, R¹ represents a hydrocarbon group having 1 to 24 carbon atoms, R² represents a hydrocarbon group having 1 to 6 carbon atoms, R³ represents a hydrocarbon group having 6 to 24 carbon atoms and having a branched chain, R⁴ and R⁵ represent a hydrocarbon group having 1 to 6 carbon atoms, which may be substituted, R⁶ represents a hydrogen atom or a hydrocarbon group having 1 to 18 carbon atoms, L represents *-O-C(O)- or *-C(O)O-, a represents an integer of 1 to 12, and b, c, and d represent an integer of 1 to 4.

SELECTIVE DELIVERY OF ONCO-SUPPRESSIVE MIRNA (MIR126) TO METASTATIC MELANOMA CELLS RESISTANT TO THERAPIES

Resumen de: WO2024189572A1

The present invention discloses carriers with an onco-suppressive agent and selectively directed to a tumoral target for the treatment of metastatic melanoma resistant to a target therapy.

ANTIBODY SPECIFICALLY BINDING TO CLAUDIN18.2 AND PREPARATION METHOD THEREFOR AND USE THEREOF

Resumen de: EP4682169A1

Provided is an anti-Claudin18.2 nanobody or a binding fragment thereof. The antibody has a good specificity, and a Claudin18.2-targeting immune effector cell prepared using the antibody shows a good therapeutic effect in the treatment or amelioration of diseases having positive expression of Claudin18.2.

LIPID NANOPARTICLES FOR DIRECT DELIVERY

Resumen de: EP4681739A1

The present invention relates to the field of lipid nanoparticles (LNP) and direct delivery of an active agent to a cell. It provides lipid nanoparticle constructs that are particularly useful for delivery of active agents, e.g., of RNA, preferably, mRNA, to cells. The lipid nanoparticle constructs comprise a specific neutral hydrophilic solid lipid nanpoparticle (SLP) and a targeting agent associated with the nanoparticle, e.g. a single domain antibody (sdAb), which may, for example target CD4. The lipid nanoparticle construct may comprise an active agent, and it may be used for targeting a cell such as a T cell. Pharmaceutical compositions comprising the nanoparticle constructs are also provided, in particular for use in targeting a cell. The invention also provides a composition or kit suitable for preparing the lipid nanoparticle construct of the invention.

DELIVERY OF GENE EDITING SYSTEMS AND METHODS OF USE THEREOF

Resumen de: AU2024236558A1

The present disclosure describes improved LNP-based nucleobase editing systems and therapeutics for use in treating a disease. In particular, the disclosure describes improved LNPs, including novel and improved ionic lipids for making LNPs, that enhance the targeted delivery of LNP-based nucleobase editing systems and therapeutics based on linear and/or circular mRNAs. The improved LNPs protect linear and/or circular mRNA payloads from degradation and clearance while achieving targeted systemic or local delivery for use as enhanced nucleobase editing systems and/or therapeutic agents.

UNIVERSAL INFLUENZA MRNA VACCINE AND USE THEREOF

Resumen de: EP4682174A1

Provided is a universal influenza mRNA vaccine. The protein encoded by the universal influenza mRNA vaccine comprises a matrix protein 2 extracellular domain (M2e), a hemagglutinin (HA) stem LAH region and a nucleoprotein (NP) of an influenza A virus. In addition, further provided is the use of the universal influenza mRNA vaccine in a mouse animal model. The universal influenza mRNA vaccine can induce strong humoral immune and cellular immune responses, and can protect animal model mice against various influenza A viruses. The universal influenza mRNA vaccine is safe and effective, and has a rapid production platform.

M@PLGA-10BX复合物及其制备方法和应用

Resumen de: CN121360099A

本发明属于药物递送技术领域，具体涉及一种M@PLGA‑10BX复合物及其制备方法和应用。本发明通过制备富集10B的氮化硼(h‑10BN)；提取巨噬细胞RAW264.7的细胞膜；制备装载h‑10BN的聚乳酸‑羟基乙酸共聚物(PLGA)纳米颗粒；最终制备基于巨噬细胞膜的仿生纳米平台M@PLGA‑10BN。本发明制备的仿生纳米平台粒径形貌均一，具有较高的生物安全性，对各组织脏器均无明显损伤。既可作为硼化合物递送的通用平台，又可作为一种免疫激活剂，适用于静脉注射给药并且拓展了硼中子俘获疗法(BNCT)在胶质母细胞瘤(GBM)治疗中的应用。

一种靶向肺癌的双响应级联交联水凝胶及其制备方法

Resumen de: CN121360069A

本发明涉及生物医学材料技术领域，提供了一种靶向肺癌的双响应级联交联水凝胶。该水凝胶包含相A和相B：相A包含透明质酸‑苯硼酸和四臂聚乙二醇‑巯基；相B包含聚乙二醇二丙烯酸酯、光引发剂LAP以及负载Tasquinimod、PD‑L1抗体和MMP‑2敏感肽的功能化上转换纳米颗粒。该水凝胶通过酸响应初步成胶阻止扩散，并借助光触发强化交联定型，实现可注射性与高机械强度的统一，同时通过时序控制释放策略，快速释放PD‑L1抗体激活免疫应答，并缓释Tasquinimod阻断免疫抑制，避免药物拮抗。本发明水凝胶在经支气管镜超声引导透支气管壁针吸活检通道的精准注射方式下，介入精度高、定位性强，有望实现对肺癌的高效靶向治疗。

一种甲苯磺酸卢美哌隆口崩组合物及其制备方法

Resumen de: CN121360087A

本发明属于药物制剂领域，具体涉及一种甲苯磺酸卢美哌隆口崩组合物及其制备方法。以甲苯磺酸卢美哌隆为有效成分，以甲基丙烯酸和甲基丙烯酸甲酯（1：2）共聚物或单双硬脂酸甘油酯为载体制备载药纳米颗粒，通过冻干工艺形成高度多孔、遇唾液快速崩解的疏松结构，得到一种甲苯磺酸卢美哌隆口崩组合物。载体通过分子间作用力有效包封甲苯磺酸卢美哌隆，能有效遮蔽药物的苦味与麻味，同时借助纳米颗粒的小尺寸效应促进药物在唾液中快速分散并通过口腔黏膜直接吸收，避免了该药物经胃肠道吸收的严重首过效应，显著提升药物生物利用度，降低药物的使用剂量提高患者服药依从性。

柠檬皮源脂质纳米粒及其在抗肿瘤与抗炎药物递送中的应用

Resumen de: CN121360100A

本发明涉及纳米医药技术领域，具体公开了一种柠檬皮源脂质纳米粒及其在抗肿瘤与抗炎药物递送中的应用。本发明以柠檬皮为原料，采用超声辅助法获得天然脂质成分，并通过溶剂注入法成功制备得到粒径均一、包封率高的柠檬皮源脂质纳米粒（LP LNPs）。该方法工艺简便、成本低廉、原料易得，制备的LP LNPs具有良好的胶体稳定性和生物相容性。后续表征实验证实，LP LNPs具有更高的细胞摄取效率和良好的生物安全性。随后将阿霉素或柚皮素包裹于LP LNPs中，可以提高药物的稳定性和生物利用度，最终实现更强的抗肿瘤及抗炎效果。因此，在药物递送领域具有重要的潜在应用价值和广阔的发展前景。

一种基于蔓菁的润肺护嗓复合组合物及其制备方法

Resumen de: CN121360158A

本发明公开了一种基于蔓菁的润肺护嗓复合组合物及其制备方法。该组合物包括蔓菁活性组分、银耳多糖、改性蜂胶纳米粒、岩藻依聚糖、枇杷叶提取物和薄荷脑‑环糊精包合物。制备过程中，首先通过硫代葡萄糖苷酶将蔓菁中的硫代葡萄糖苷高效转化为萝卜硫素等活性物质；然后设计合成改性蜂胶纳米粒对蜂胶黄酮类及酚酸类物质进行包埋，提高其稳定性和生物利用度；最后将各组分整合，通过复合凝胶与喷雾干燥等工艺制得最终产品。本产品萝卜硫素含量达9.17mg/g，对金黄色葡萄球菌和肺炎链球菌的抑菌圈直径分别达17.6mm和16.97mm，小鼠咳嗽抑制率高达57.14%，解决了传统产品活性成分不稳定、功效单一的问题。

一种靶向APCs的脂质纳米颗粒及其应用

Resumen de: CN121360097A

本发明提供一种靶向APCs的脂质纳米颗粒及其应用。所述脂质纳米颗粒包括可电离脂质、甾醇类化合物、辅助脂质、聚合物和RNA药物，通过对制备脂质纳米颗粒的配方进行筛选，得到低免疫原性的配方，所述配方制得的脂质纳米颗粒被APCs特异性摄取。所述脂质纳米颗粒表面还可连接靶向配体，所述配体可以特异性地与APCs表面的受体结合，从而促进APCs与脂质纳米颗粒的相互作用与内吞。本发明提供的靶向APCs的脂质纳米颗粒还可用于自身免疫性疾病(AIDs)的治疗，其低免疫原性和高效靶向性提高了RNA递送的安全性和有效性。

一种脂质纳米颗粒冻干制剂的制备方法

Resumen de: CN120241626A

According to the preparation method of the LNP freeze-dried preparation, the particle size difference before and after LNP freeze-drying can be reduced and the product quality can be improved by adding salt into an LNP solution, adjusting the pH value or carrying out curing treatment and the like.

一种无表面活性助剂的包埋油核的壳聚糖微纳米胶囊及其制备方法

Resumen de: CN121360533A

本发明公开了一种无表面活性助剂的包埋油核的壳聚糖微纳米胶囊及其制备方法，利用纯油水液滴在一定pH下带有负电荷的特性，与带正电荷的壳聚糖进行静电吸附获得壳聚糖包覆的微纳米乳液，然后加入交联剂使其与壳聚糖在油滴界面上原位交联成壳，最终形成壳聚糖微纳米胶囊。本发明得到的壳聚糖微纳米胶囊不仅不需要额外的表面活性助剂，而且制备的微纳米胶囊成壳能力强，包封效果好，远优于常规带有表面活性剂助剂的壳聚糖微纳米胶囊。此胶囊可用于食品、药品、化妆品与健康护理品领域。

一种声磁双模诊疗剂及其制备方法与应用

Resumen de: CN121360249A

本发明提供一种声磁双模诊疗剂及其制备方法与应用，属于肿瘤诊疗剂制备技术领域。该声磁双模诊疗剂为含有纳米气囊基因的大肠杆菌诱导表达后的表面修饰磁纳米微粒；所述纳米气囊基因的核苷酸序列为NCBI：KC601845.1所示的序列，声磁双模诊疗剂中的大肠杆菌作为诊疗剂载体对肿瘤乏氧区具有主动靶向性，细菌内部包含纳米气囊，具有声响应特性；上述大肠杆菌表面修饰磁纳米颗粒，具有磁响应特性。在声磁双模成像中，首先在实时超声造影监测图像上，细菌内部表达的纳米气囊能产生增强的肿瘤超声回波信号；其次在外部变化磁场作用下，细菌表面的磁纳米颗粒在能够产生增强的肿瘤磁致振动成像效果，实现更高效的肿瘤诊断和/或治疗。

雷公藤内酯酮纳米递送系统的构建方法及其应用

Resumen de: CN121360102A

本发明属于医药技术领域，具体涉及雷公藤内酯酮纳米递送系统的构建方法及其应用。本发明构建一种兼具温敏响应与自由基清除功能的雷公藤内酯酮纳米递送系统TN‑CP NPs，并通过体内外实验验证其在类风湿性关节炎治疗中的有效性与安全性。在CIA小鼠模型中，该系统显著缓解关节肿胀、抑制炎症因子表达、改善关节组织病理损伤，并有效降低了TN引起的肝毒性与睾丸毒性，未表现出明显的血液学或全身毒性。可见，TN‑CP NPs通过温敏控释与抗氧化协同作用，实现了TN的高效、低毒递送，RA的精准治疗提供了一种安全有效的新型纳米策略，也为其他具有强活性但高毒性的天然药物的临床转化提供了参考思路。

一种用于类风湿性关节炎治疗的仿生纳米颗粒的制备方法及其应用

Resumen de: CN121360098A

本发明的目的在于提供一种用于类风湿性关节炎治疗的仿生纳米颗粒的制备方法及其应用，属于纳米生物医学材料制备技术领域，该纳米颗粒以空心碳球为载体，利用浸渍法负载铂颗粒，通过巨噬细胞膜的仿生修饰策略，构筑了一种具备类风湿性关节炎治疗的仿生纳米颗粒。该纳米颗粒可以在无光照刺激条件下产生单线态氧，并借助自身的类过氧化氢酶活性和光热性能，实现单线态氧的级联生成，对类风湿性关节炎部位异常增殖的滑膜成纤维细胞进行高效杀伤以治疗类风湿性关节炎。

一种抑制胆管癌拟素化的药物制剂及其制备方法

Resumen de: CN121360101A

本发明属于抗肿瘤药物制剂技术领域，具体涉及一种抑制胆管癌拟素化的药物制剂及其制备方法，其中，所述药物制剂包括以下重量份原料：UBE2M抑制剂10份、PLGA80‑100份、DSPE‑PEG2000‑T7 15‑20份、稳定剂5份和渗透剂8份，经计算机虚拟筛选得到的对UBE2M具有高结合力的UBE2M抑制剂，具有良好的药理活性，能够通过抑制显著抑制UBE2M活性，从而影响PHB2蛋白水平及拟素化进程，实现抗胆管癌作用效果，同时利用具有亲疏水和靶向特性的修饰材料将UBE2M抑制剂制成纳米制剂，能够有效降低药物在体内循环过程中的渗漏情况，提高在胆管癌病灶部位的蓄积。

核酸送達用の新規なイオン化可能脂質化合物

Resumen de: CN120693317A

Novel ionizable lipid compounds, compositions comprising such ionizable lipid compounds, and related methods of use thereof are disclosed. Nanoparticle compositions comprise novel lipids and additional lipids, such as phospholipids, structural lipids, and PEG lipids. The nanoparticle composition also comprises a bioactive agent, such as siRNA or mRNA, which can be used to deliver the bioactive agent to an individual in need thereof.

TRAITEMENT PAR PHOTOTHERMIE PLASMONIQUE DES CANCERS CUTANES PRESENTANT DES LESIONS ETENDUES EN UTILISANT DES NANOPARTICULES D’OR

Resumen de: FR3164393A1

L’invention se rapporte au domaine du traitement des tumeurs cutanées. Plus particulièrement, l’invention concerne l’utilisation de nanoparticules d’or pour traiter les tumeurs cutanées dont le volume est supérieur ou égal à 500 mm3. L’invention repose sur une administration de nanoparticules d’or directement dans la tumeur suivie d’une irradiation laser proche de l’infrarouge. La combinaison des nanoparticules d’or et de la photothérapie plasmonique, en traitement répété à 11 à 17 jours d’intervalle, permet une disparition complète d’une tumeur cutanée avec lésion étendue, sans récidive.

眼障害の治療のための薬物コンジュゲート

Resumen de: US2025387503A1

The present invention relates to drug conjugates or pharmaceutically acceptable salts thereof comprising hyaluronic acid (HA) hydrogel microspheres, pharmaceutical compositions and methods of using such conjugates for treatment of ocular disorders, and methods of making the conjugates.

核酸分子

Nº publicación: JP2026501863A 16/01/2026

Solicitante:

アストラゼネカ・アクチエボラーグ

Resumen de: CN120957744A

The present disclosure relates to a nucleic acid molecule comprising a 5 '-UTR and/or 3'-UTR sequence that yields a high level of translation. Aspects of the disclosure further relate to nucleic acid molecules suitable for use as vaccines for the treatment and prevention of infectious diseases, including those caused by coronavirus, compositions comprising the nucleic acid molecules, and methods of treating or preventing infectious diseases.